The use of bisphosphonates has become important in preventive treatment of osteoporosis in patients who receive glucocorticoids for underlying diseases including autoimmune hepatitis and primary biliary cirrhosis and following transplants. This treatment has resulted in BMD improvement in all of these types of patients.
El uso de bifosfonatos toma importancia en el tratamiento de prevención de osteoporosis en pacientes que reciben glucocorticoides para su enfermedad de base; hepatitis autoinmune, cirrosis biliar primaria, etc., en donde han demostrado el mejoramiento de la DMO, al igual que en pacientes pre y postrasplante.